Table 5.
Treatment modalities and patient outcomes in both VAP groups
| Variables | blaNDM-1-positive Acinetobacter VAP infection (n=42) | blaNDM-1-negative Acinetobacter VAP infection (n=22) | |||||||
|---|---|---|---|---|---|---|---|---|---|
|
| |||||||||
| Colistin monotherapy | Colistin + imipenem | P-value | Total | Colistin monotherapy | Colistin + imipenem | P-value | Total | P-value | |
|
| |||||||||
| N (%) | 22 (52.4) | 20 (47.6) | 42 (100) | 14 (63.6) | 8 (36.4) | 22 (100) | |||
| Time to start antibiotics, n (%) | |||||||||
| • Early (within 24 hours) 60/64 | 20 (90.9) | 20 (100) | 40 (95.2) | 12 (85.7) | 8 (100) | 20 (90.9) | |||
| • Late (>24 hours) 4/64 | 2 (9.1) | 0 | 2 (4.8) | 2 (14.3) | 0 | 2 (9.1) | |||
| Duration of antibiotics treatment (days), median (minimum–maximum) | 11 (7–14) | 7 (4–11) | 0.009* | 5 (4–14) | 11 (7–14) | 6 (5–10) | 0.0032* | 5 (5–14) | 0.215 |
| Effectiveness of antibiotics treatment, n (%) | |||||||||
| • Complete clinical response 40/64 (62.5%) | 8 (36.3) | 17 (85) | 0.0013* | 25 (59.5) | 8 (57.1) | 7 (87.5) | 0.141 | 15 (68.2) | 0.461 |
| • Treatment failure 24/64 (37.5%) | 14 (63.7) | 3 (15) | 17 (40.5) | 6 (42.9) | 1 (12.5) | 7 (31.8) | |||
| Patient outcomes, n (%) | |||||||||
| • Recurrent VAP (relapse) 8/64 (12.5%) | 5 (22.7) | 1 (5) | 0.101 | 6 (14.2) | 1 (7) | 1 (12.5) | 0.674 | 2 (9) | 0.550 |
| • Deaths 30/64 (46.8%) | 17 (77.3) | 10 (50) | 27 (64.3) | 2 (14.3) | 1 (12.5) | 3 (13.6) | |||
| • Improvement and discharge 34/64 (53.2%) | 5 (22.7) | 10 (50) | 0.654 | 15 (35.7) | 12 (85.7) | 7 (87.5) | 0.906 | 19 (86.4) | 0.0001* |
Note:
*
Statistical significance.
Abbreviations: blaNDM, New Delhi metallo-β-lactamase; VAP, ventilator-associated pneumonia.